Table 4.
Differences in patient characteristics between patients with and without residual glucocorticoid production and in patients with combined glucocorticoid and mineralocorticoid production compared with patients with no residual production.
| N (%) or Median (minimum, maximum) or Mean (±SD) | ||||||
|---|---|---|---|---|---|---|
| Variable | GC+ | GC– | P | GC+, MC+ | GC–, MC– | P |
| No. females (%) | 25 (43.1) | 91 (67.9) | 0.001a | 16 (66.7) | 89 (67.4) | 1.000 |
| Age, years | 46.2 ± 14.8 | 49.2 ± 12.3 | 0.142 | 42.6 ± 14.4 | 49.3 ± 12.3 | 0.020 |
| DD, years | 6 (0-44) | 13 (0-53) | 0.001a | 5.5 (0.5-26) | 13.5 (0.0-53.0) | 0.002a |
| Age at diagnosis, years | 36 (12-64) | 31.5 (11-63) | 0.202 | 33.5 (13-64) | 31 (11-63) | 0.673 |
| Adrenal crisis ever, n (%) | 38 (65.6) | 98 (73.7) | 0.252 | 15 (62.5) | 96 (73.3) | 0.406 |
| Adrenal crisis at diagnosis, no (%) | 34 (58.6) | 79 (59.4) | 0.920 | 13 (54.2) | 78 (59.5) | 0.790 |
| Adrenal crisis last year, n (%) | 11 (19.0) | 19 (14.3) | 0.414 | 5 (20.8) | 19 (14.5) | 0.630 |
| Infectious illness last year, n (%) | 22 (37.9) | 49 (37.1) | 0.915 | 7 (29.2) | 49 (37.7) | 5.710 |
| CVD, no. (%) | 0 (0) | 2 (1.5) | 0.350 | 0 (0) | 2 (1.5) | 1.000 |
| Osteoporosis, n (%) | 4 (6.9) | 12 (9.0) | 0.626 | 0 (0) | 12 (9.2) | 0.259 |
| APS2, no. (%) | 29 (50) | 80 (59.7) | 0.277 | 14 (58.3) | 78 (59.1) | 0.945 |
| Salt cravings, n (%) | 14 (24.1) | 33 (24.6) | 0.942 | 8 (33.3) | 32 (24.2) | 0.494 |
| Orthostatic hypotension, n (%) | 14 (24.1) | 18 (13.4) | 0.068 | 8 (33.3) | 18 (13.6) | 0.037 |
| Fatigue, n (%) | 22 (37.9) | 54 (40.3) | 0.758 | 7 (29.2) | 54 (40.5) | 0.391 |
| Loss of appetite, n (%) | 6 (10.3) | 6 (4.5) | 0.123 | 2 (8.3) | 6 (4.5) | 0.786 |
| GI-symptoms, n (%) | 14 (24.1) | 25 (18.7) | 0.386 | 5 (20.8) | 25 (18.9) | 1.000 |
| Muscle/ joint pain, n (%) | 17 (29.3) | 33 (24.6) | 0.497 | 4 (16.7) | 33 (25.0) | 0.534 |
| Sleeping disturbances, n (%) | 20 (34.5) | 36 (26.9) | 0.286 | 11 (45.8) | 36 (27.3) | 0.114 |
| Nausea, n (%) | 4 (6.9) | 10 (7.5) | 0.890 | 4 (16.7) | 10 (7.6) | 0.296 |
| BMI, kg/m2 | 25.1 (18.1-37.1) | 24.1 (16.6-38.3) | 0.257 | 25.8 (18.1-37.1) | 24.1 (16.6-38.3) | 0.512 |
| SBP, mmHg | 120.5 (90-150) | 120 (84-169) | 0.019 | 120 (90-150) | 120 (84-169) | 0.356 |
| DPB, mmHg | 76 (55-93) | 76 (50-95) | 0.537 | 75 (55-90) | 76 (50-95) | 0.737 |
| Hyperpigmentation, n (%) | 29 (50.0) | 71 (53.4) | 0.667 | 11 (45.8) | 70 (53.4) | 0.643 |
| HCeq, mg/day | 20 (10-50) | 20 (7.4-40) | 0.875 | 20 (10-40) | 20 (7.5-40) | 0.375 |
| HCeq, mg/kg/day | 0.31 (0.14-0.58) | 0.32 (0.12-0.78) | 0.179 | 0.31 (0.14-0.55) | 0.32 (0.03-0.3) | 0..484 |
| HCeq, mg/m2/day | 7.4 (3.3-13.3) | 7.7 (2.8-15.4) | 0.179 | 7.9 (3.3-12.0) | 7.8 (2.8-15.4) | 0.839 |
| FC, mg/ day | 0.10 (0.05-0.20) | 0.10 (0.03-0.30) | 0.156 | 0.10 (0.05-0.12) | 0.10 (0.03-0.30) | 0.014 |
| RAND-36 PF | 95 (55-100) | 95 (25-100) | 0.710 | 95 (80-100) | 95 (35-100) | 0.395 |
| RAND-36 RP | 100 (0-100) | 100 (0-100) | 0.444 | 100 (0-100) | 100 (0-100) | 0.087 |
| RAND-36 BP | 74 (22-100) | 84 (12-100) | 0.835 | 84 (22-100) | 83 (12-100) | 0.363 |
| RAND-36 GH | 67 (17-100) | 67 (5-95) | 0.879 | 67 (20-97) | 67 (10-100) | 0.718 |
| RAND-36 VT | 65 (5-100) | 60 (5-95) | 0.407 | 65 (5-100) | 60 (5-95) | 0.198 |
| RAND-36 SF | 87.5 (25-100) | 87.5 (12.5-100) | 0.991 | 87.5 (25-100) | 87.5 (12.5-100) | 0.653 |
| RAND-36 RE | 100 (0-100) | 100 (0-100) | 0.374 | 100 (0-100) | 100 (0-100) | 0.605 |
| RAND-36 MH | 80 (36-100) | 84 (44-100) | 0.534 | 76 (36-100) | 84 (55-100) | 0.156 |
| AddiQol-30 | 90.9 ± 12.7 | 89.6 ± 10.3 | 0.476 | 91 ± 11.7 | 89.5 ± 10.3 | 0.5230 |
| Hb, g/dL | 14.5 ± 1.2 | 13.8 ± 1.1 | 0.001a | 14.6 ± 1.2 | 13.8 ± 1.1 | 0.004a |
| HbA1C, mmol/mol | 35 (28-53) | 35 (24-43) | 0.657 | 35 (28-50) | 35 (24-43) | 0.806 |
| S-TSH, mIE/L | 2.6 (0.05-12.7) | 2.55 (0.01-13.2) | 0.977 | 1.8 (0.06-7.0) | 2.6 (0.01-13.2) | 0.140 |
| S-fT4, pmol/L | 15.0 (10.6-23.0) | 15.0 (10.6-25.0) | 0.983 | 16.2 (11-23) | 15.0 (10.6-25.0) | 0.262 |
| S-cobalamin, pmol/L | 368 (174-753) | 372 (140-1476) | 0.964 | 379 (210-605) | 372 (140-1476) | 0.490 |
| S-ferritin µg/L | 116 (15-446) | 101 (6-621) | 0.394 | 91 (15-297) | 102 (6-621) | 0.416 |
| S-creatinine, µmol/L | 77 (60-150) | 73 (39-116) | 0.006a | 75 (60-96) | 73 (39-116) | 0.405 |
| S-sodium, mmol/L | 139 (131-145) | 140 (131-148) | 0.237 | 138 (136-142) | 140 (131-148) | 0.005a |
| S-potassium, mmol/L | 4.1 (3.5-4.9) | 3.9 (3.0-5.1) | 0.008a | 4.2 (3.5-4.6) | 3.9 (3.0-5.1) | 0.036 |
| S-cholesterol, mmol/L | 5.1 ± 1.0 | 5.1 ± 0.9 | 0.630 | 5.1 ± 1.2 | 5.1 ± 1.0 | 0.827 |
| S-HDL-C, mmol/L | 1.4 (0.1-2.2) | 1.7 (0.6-2.7) | 0.001a | 1.5 (1.1-2.2) | 1.7 (0.6-2.7) | 0.224 |
| S-LDL-C, mmol/L | 3.2 ± 1.0 | 3.1 ± 0.8 | 0.406 | 3.3 ± 1.2 | 3.1 ± 0.8 | 0.292 |
| S-triglycerides, mmol/L | 1.3 (0.4-5.8) | 1.3 (0.1-9.7) | 0.609 | 1.2 (0.5-3.2) | 1.3 (0.1-9.7) | 0.702 |
| PRC, mU/L | 75.7 (0.7-915.0) | 49.0 (0.6-658.0) | 0.055 | 152 (22-915) | 46 (1-658) | <0.001a |
| P-ACTH, pmol/L | 123 (26-278) | 147 (1-278) | 0.123 | 85 (26-278) | 147 (1-278) | 0.087 |
Abbreviations: APS2, autoimmune polyendocrine syndrome type 2; BMI, body mass index; BP, bodily pain; CVD, cardiovascular disease; DBP, diastolic blood pressure; DD; disease duration; FC, fludrocortisone dosage; fT4, free thyroxine; GC+, residual glucocorticoid production; GC–, no residual glucocorticoid production; GH, general health; GI, gastrointestinal; Hb, hemoglobin; HbA1c, glycated hemoglobin; HCeq, hydrocortisone equivalent dosage; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MC+, residual mineralocorticoid production; MC–, no residual mineralocorticoid production; MH, general mental health; P-ACTH, plasma adrenocorticotropic hormone; PF, physical functioning; PRC, plasma renin concentration; RAND, health survey; RE, role limitations caused by emotional problem; RP, role limitations caused by physical health problems; S-, serum; SBP, systolic blood pressure; SD, standard deviation; SF, social functioning; TSH, thyroid-stimulating hormone; VT, vitality.
aStatistically significant at 0.01 level.